News

PipelineReview.com18h
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
LAVAL, Canada and CUPERTINO, CA, USA I July 29, 2025 I Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and ...
PipelineReview.com17h
LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
REDWOOD CITY, CA, USA & SHENZHEN, China I July 29, 2025 I LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a ...
PipelineReview.com18h
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol ...
PipelineReview.com18h
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs of ...
PipelineReview.com18h
Formation Bio Licenses First-in-Class Anti-CD226 Autoimmune Program from IMIDomics
The anti-CD226 mAb adds to Formation Bio’s growing pipeline which currently includes programs in immunology, dermatology, and rheumatology and reflects the company’s focus on first- and best-in-class ...
PipelineReview.com1d
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up ...
PipelineReview.com1d
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Indication SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE ...
PipelineReview.com1d
Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise ...
PipelineReview.com1d
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
PARIS, France I July 28, 2025 I Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received ...
PipelineReview.com2d
PipelineReview.com. Biopharmaceutical News & Clinical Trials
Get the latest biopharma news, clinical trial updates, and industry insights at PipelineReview.com. Discover innovative therapies and regulatory news.
PipelineReview.com1d
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to ...
PipelineReview.com1d
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...